Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company strategically focused on acquiring and managing businesses across high-growth sectors, including healthcare, technology, and infrastructure. With a robust leadership team committed to operational excellence and innovation, Concentra actively seeks to optimize its portfolio through strategic investments and management practices. This proactive approach enables Concentra to effectively leverage emerging market trends and growth opportunities, making it a compelling choice for institutional investors seeking diversification in dynamic and high-potential markets.
| Revenue (TTM) | $2.29B |
| Gross Profit (TTM) | $670.56M |
| EBITDA | $461.61M |
| Operating Margin | 19.30% |
| Return on Equity | 47.10% |
| Return on Assets | 8.16% |
| Revenue/Share (TTM) | $17.91 |
| Book Value | $3.74 |
| Price-to-Book | 9.30 |
| Price-to-Sales (TTM) | 2.15 |
| EV/Revenue | 2.808 |
| EV/EBITDA | 14.13 |
| Quarterly Earnings Growth (YoY) | 47.00% |
| Quarterly Revenue Growth (YoY) | 10.00% |
| Shares Outstanding | $127.52M |
| Float | $115.27M |
| % Insiders | 9.65% |
| % Institutions | 90.59% |
Volatility is currently expanding
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The company is growing, widening its margins, paying down debt, and paying a dividend all at the same time. Wall Street sees more upside ahead and has tagged the stock with a full Buy rating.
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Concentra Group Holdings Parent, rated BUY, has surged 78% YTD, driven by market share gains and strong operating leverage. CON beat 2Q26 earnings estimates, with revenue up 10% YoY and adjusted EBITDA up 22.5%, aided by higher patient revenue per visit. Future growth may be propelled by additional state-level workers' compensation reimbursement increases and a robust M&A pipeline.
Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?
Does Concentra Group (CON) have what it takes to be a top stock pick for momentum investors? Let's find out.
Concentra Group, QuinStreet and Arrow Electronics pair broker rating upgrades with strong projected earnings growth, making them stocks to consider.
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CON and any ticker you trade — then tracks every position and per-strategy win rate.
